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1 Introduction
The International Human Genome Sequencing 
Consortium, which launched the Human Genome 
Project in 1990, announced a draft sequence 
of the human genome in cooperation with 
Celera Genomics in 2001[1,2]. The consortium 
released the finished version of the sequence[3] 
and announced the completion of the project in 
October 2004.
The complete human genome sequence was 
obtained using DNA samples taken from only a 
few people. The completion of the project led 
to the post-genome era, and the next important 
task is to apply the genome information of each 
individual to medicine and promote personalized 
medicine.
T h i s  a r t i c l e  d i s c u s s e s  a d v a n c e s  i n  
pharmacogenomics *1 and molecular - targeted 
anticancer drugs *2, both of which are rapidly 
evolving technologies, and suggests future 
initiatives to achieve social acceptance and public 
understanding of personalized medicine through 
the provision of genome-related information to 
the public (Figure 1). These issues need to be 
addressed to successfully promote personalized 
medicine.
Figure 1 : Outline of this article
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2 Personalized medicine
2-1 About personalized medicine
In Japan, “personalized medicine” is sometimes 
cal led “kobetsuka iryou”, which is a direct 
translation, or “order -made iryou”, which is 
a Japanese -English phrase. All of these terms 
descr ibe the implementat ion of medicine 
(prevention, diagnosis and therapy) based on 
genome information including molecular/genetic 
data or molecular/genetic aberrations responsible 
for diseases and symptoms.
In conventional medicine, doctors chose 
drugs and the method of administration (dosage 
and frequency) based on their experience and 
opinions (so - called “doctor’s prescription”). 
The differences in drug efficacy and side effects 
among individuals were vaguely explained by 
the difference in their “constitutions”. However, 
as the need for ev idence - based medicine 
became more widely acknowledged, doctors 
began to place emphasis on scientific validity 
when choosing therapeutic strategies. Scientific 
validation at a molecular level requires a vast 
amount of research using the results from the 
genome project and post - genome research. 
This impl ies that we have entered a stage 
where we now recognize that the difference in 
“constitutions” is in fact the difference in genes 
and genome information. (In this paper, the 
term “molecule” principally refers to a DNA, 
RNA or protein. The term “genome” originally 
referred to the entire set of genes, but since 
many biolog ica l  phenomena involve DNA 
regions other than genes, the term “genome” 
used here refers to an individual’s complete set 
of DNA. Thus, “molecular data” includes all the 
information provided by the DNA sequence, 
mRNA expression, protein expression, etc., and 
the measurements and analyses of these data are 
referred to as “molecular diagnoses”.)
In parallel with the progress of the genome 
project, the concept of “genome -based drug 
discovery” has attracted attention in drug 
R&D. This concept aims at the development 
of drugs that target the molecules responsible 
for diseases. Pharmaceutical drugs that are 
developed through genome-based drug discovery 
potentially show high specificity compared to 
conventional drugs and are therefore expected 
to reduce the risk of side effects and increase 
their therapeutic efficacy. Reduced risk of side 
effects is an especially important issue, as side 
effects were found to be the fourth to sixth most 
common causes of death in the U.S. [4]. According 
to research repor ted in 1998, in the U.S., 
approximately 2.2 million (6.7%) of hospitalized 
patients suffered from severe side effects, 110,000 
(0.32%) of whom died. Thus, the realization of 
personalized medicine is an extremely urgent 
task to reduce the side effects of drugs and secure 
public safety.
Personalized medicine provides appropriate 
treatment to patients based on the difference in 
genome information or molecules responsible for 
diseases (Figure 2).
“The five rights” is a slogan originally intended 
to remind nurses of the points to be confirmed 
at injection or administrat ion of drugs to 
patients, but it is also relevant to the concept of 
personalized medicine.
The min imum standard of  pract ice for  
medication administration is checking “the five 
rights” to provide patient safety.
The Five Rights:
• Right Patient
• Right Drug
• Right Dose
• Right Time
• Right Route
“Right patient” and “right drug” imply the use 
of molecular-targeted drugs developed through 
genome-based drug discovery, i.e. the recognition 
of molecular aberrations responsible for diseases 
or symptoms and the administration of drugs that 
exclusively act on and remove aberrations. “Right 
patient” and “right dose” imply the importance 
of pharmacogenomics in drug -metabolizing 
enzymes etc., discussed in the next chapter, i.e. 
prescription of appropriate dosage based on the 
difference in drug response among individuals. 
In addition to drug-metabolizing enzymes, steps 
such as drug absorption, distribution, metabolism 
and excretion (ADME) all play an important role 
in drug metabolism. “Right dose”, “right time” 
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and “right route” are therefore important factors 
to consider in understanding the difference in 
ADME among individuals.
2-2 Pharmacogenomics
The Food and Drug Administration (FDA) 
announced a dra f t plan for “Guidance for 
Industry, Pharmacogenomic Data Submissions” 
in November 2003 and its final plan in April 
2005. In response to the FDA’s action in June 
2004, the Evaluation and Licensing Division of 
the Pharmaceutical and Food Safety Bureau in the 
Ministry of Health, Labour and Welfare recruited 
opinions and information from pharmaceutical 
makers on the current status of clinical trials 
using genome tests and announced “Submission 
of information to government agencies for the 
preparation of guidelines for the application of 
pharmacogenomics to clinical trials of drugs” 
(Notification No. 0318001 from the Evaluation 
and Licensing Division of the Pharmaceutical and 
Food Safety Bureau) in March 2005. These actions 
imply that pharmacogenomics has progressed 
from the research stage to the practical stage, and 
now requires data submission for application to 
clinical drug trials.
Pharmacogenomics is defined as the analyses 
of drug response based on the genetic data of 
individuals. It is a system to predict and assess 
the difference in drug efficacy and side effects 
among individuals (conventionally explained 
as “constitutions”) based on the results of 
comprehensive and systematic analyses of 
genome information. The typical research 
targets of pharmacogenomic studies are the 
SNPs (single nucleotide polymorphisms) found 
in the drug-metabolizing enzyme genes CYPs 
(cytochrome P450). Various molecules involved 
in in vivo kinetics, such as excretion and uptake 
of drugs (pharmacokinetics), also affect drug 
efficacy and side effects and are therefore subject 
to pharmacogenomic studies.
As in the case of Iressa, which will be discussed 
below, the difference in genes encoding drug 
target molecules on which the drugs directly act 
can be correlated with the difference in drug 
efficacy. Pharmacogenomics of drugs, drug target 
molecules and the downstream signaling pathway 
are as important in drug development as that of 
drug metabolism and dynamics.
A SNP is a single DNA base pair variation 
shared by a human population greater than a 
certain size. SNPs occur at a frequency of 1% 
or higher in the human population and are 
distinguished from mutations that occur at a 
lower frequency. In 1999, the SNP Consortium 
Figure 2 : Personalized medicine
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wa s  e s t ab l i shed  by  t he  Wel lcome Tr u s t  
and approximately ten pharmaceutical and 
technology companies. Their research work 
and many other SNP projects have revealed that 
SNPs are evenly distributed across the genome 
at a frequency of one SNP per 100-1,000 bp, i.e. 
there are 3-10 million SNPs in the entire human 
genome. SNPs found in gene regions that encode 
proteins or promoter regions that regulate gene 
expression exert various changes in phenotypes 
(Figure 3). Thus, SNPs in the above-mentioned 
CYPs possess considerable clinical significance 
in terms of drug metabolism. European countries 
and the U.S. FDA approved DNA chips to identify 
SNPs in CYPs as ex vivo diagnostic agents in 
September and December 2004, respectively. 
Moreover, it is known that the development of 
side effects of the anticancer agent Camptosar 
is related to the difference in the activity of its 
metabolic enzyme (conjugating enzyme UGT1A1). 
Since the activity of the enzyme is affected by 
SNPs in the transcriptional region of the gene 
encoding the enzyme, the FDA revised the labels 
attached to this anticancer drug in July 2005 and 
included the list of relevant SNPs and directions 
for dosage regulation based on the enzyme 
activity of patients[5]. Regarding the current state 
of SNP research in Japan, R&D of SNP analysis 
techniques and research on the involvement of 
SNPs in diseases are currently being conducted 
at the SNP Research Center of RIKEN and the 
Institute of Medical Science of the University of 
Tokyo[6, 9].
2-3 Molecular-targeted anticancer drugs
Pharmacogenomics uses genome information 
to analyze the in vivo del ivery process of 
drugs, from their ingestion to their arrival at the 
target molecules. In contrast, “genome-based 
drug discovery” uses genome information to 
discover the molecules responsible for diseases 
and develop drugs (molecular- targeted drugs) 
targeted at these molecules.
Together with the progress in the Human 
Genome Project, causative genes of diseases 
have been vigorously searched for and analyzed. 
In par t icu lar, cancer - related research has 
advanced rapidly due to the timely integration 
of clinical research with basic research; for 
example, research on the mechanism of cancer 
development was integrated with cell cycle 
and intracellular signaling mechanism studies, 
and research on the action mechanism of 
anticancer agents was integrated with studies 
on DNA replication, cell division and cell death 
induction. The results of these studies led to the 
development of the first anticancer drugs based 
on molecular mechanisms. To date (as of July 
2005), four molecular-targeted anticancer drugs 
have been approved and used in Japan; Herceptin 
(breast cancer), Rituxan (B cell non-Hodgkin’s 
lymphoma), Glivec (chronic myeloid leukemia 
CML and gastrointestinal stromal tumor GIST) 
and Iressa (lung cancer), al l of which were 
developed by U.S. or European pharmaceutical 
companies (Figure 4).
These molecular- targeted anticancer agents 
act on di f ferent target molecules through 
different mechanisms (Herceptin and Rituxan 
are antibodies and Glivec and Iressa are kinase 
inhibitors), but were all developed through a 
common drug development strategy. Each of 
Figure 3 : SNPs
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these drugs target molecular aberrations that are 
specific to each disease and act exclusively on 
patients that possess the aberrations.
Herceptin is an antibody that recognizes HER2, 
a growth factor receptor that penetrates the cell 
membrane. After recognizing and binding to 
HER2, which is located on the surface of cancer 
cells, Herceptin activates the antibody-dependent 
cell damage mechanism and specifically exerts an 
antitumoral activity on HER2-expressing cancer 
cells. Rituxan is also a specific antibody that 
recognizes the CD20 antigen, which is specific to 
some tumors. Glivec exerts antitumoral activity 
on chronic myeloid leukemia (CML) through 
the inhibition of Bcr-Abl tyrosine kinase, which 
is encoded by the Bcr -Abl gene, a causative 
gene of CML produced through chromosomal 
translocation. The drug also inhibits KIT tyrosine 
kinase and therefore exerts an antitumoral 
activity on KIT-positive gastrointestinal stromal 
tumor (GIST). Iressa acts through a mechanism 
similar to Herceptin and inhibits the kinase 
activity of EGFR, another growth factor receptor 
that penetrates the cell membrane.
In order to choose the “right drug” and the 
“right dose”, confirmation of the molecular 
information of each patient is a prerequisite 
to implement personalized medicine. Thus, 
molecular diagnosis is indispensable for the 
appropriate use of molecular-targeted drugs or 
drugs whose metabolism depends on SNPs of 
CYPs.
This is also implied by the indications attached 
to these drugs; Herceptin “should be used for 
metastatic breast cancer patients with HER2 
overexpression”, Rituxan “should exclusively 
be used for CD20 -positive patients confirmed 
through immunohistological staining or f low 
cytometry”, and Glivec “should be used for 
patients diagnosed chronic myeloid leukemia 
through chromosomal or genetic screening 
or KIT-positive gastrointestinal stromal tumor 
through an immunohistological test”. Before 
using these molecular-targeted anticancer agents, 
immunohistological tests or chromosomal or gene 
screening must be performed to confirm whether 
their administration is appropriate.
Described below is an episode that demonstrates 
the importance of pharmacogenomic analysis of 
target molecules of anticancer agents to confirm 
the adequacy of anticancer agent administration.
In Ju ly 2002,  I ressa was approved as a  
therapeutic agent for lung cancer in Japan before 
approval in any other country. The drug exerted 
high anticancer activities including cancer 
regression in some patients, but often induced 
Figure 4 : Molecular-targeted anticancer drugs
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severe side effects such as interstitial pneumonia. 
Later, the drug was concluded to have “no 
survival advantage” based on the results of the 
first analysis of a worldwide clinical trial.
However, in April 2004, it was reported that 
the drug was highly effective in patients that 
have mutations in EGFR, the target molecule of 
Iressa [7, 8]. In Japan, extensive research on gene 
expression and SNP analysis for the prediction 
of drug response and side effects of Iressa are 
being performed, with the main initiative carried 
out by the Institute of Medical Science of the 
University of Tokyo [9]. Arguments concerning the 
efficacy and approval of the drug are not relevant 
to this report and will not be discussed here any 
further. Nevertheless, the emphasis placed on 
genetic diagnosis to detect mutations in the target 
molecule of Iressa demonstrates that personalized 
medicine has already been implemented in the 
form of genetic diagnosis in the clinical setting.
2-4 Translational research: clinical studies
Cancer therapy using molecular - targeted 
anticancer agents and medication regimens based 
on pharmacogenomics present an excellent 
opportunity to return the outcomes of scientific 
research to the public. That is, the results of basic 
scientific research are utilized for drug discovery 
and then fed back to clinical practice.
Advances in molecular biology have elucidated 
development mechanisms of many diseases, 
and drugs that target these mechanisms or 
molecules involved in these mechanisms have 
been intensively researched and developed 
worldwide. A drug for which the efficacy has 
been demonstrated in vitro will not be approved 
as a drug until its in vivo efficacy has been 
demonstrated in the human body.
Dr ug ef f icac y  i n  the  hu man body was  
conventionally demonstrated in clinical trials 
conducted by pharmaceutical companies for 
commercialization of drugs, but the revision 
of Pharmaceutical Affairs Law has also enabled 
researchers to conduct clinical trials. Moreover, 
systems to facilitate translational research that 
bridges the gap between basic research and 
clinical research have been improved[10].
Since drug efficacy ultimately needs to be 
confirmed in humans, not only clinical trials 
of drug candidates, but also epidemiological 
research including genetic analysis must be 
actively promoted. Fur thermore, the high 
sensitivity to Iressa seems to be associated with 
“Japanese (Asian)” and “females”. In consideration 
of such “genetic difference among races” and 
“genetic difference among sexes”, we should 
perform genetic analysis and research locally 
and avoid the direct application of research 
results obtained in the U.S. and European 
countries to the Japanese population. Genetic 
differences among races must be considered 
by conducting bridging studies with Japanese 
subjects to confirm the validity of data obtained 
from clinical trials conducted overseas. Indeed, 
a drug has been descr ibed that has been 
demonstrated to be effective only in a particular 
race (African-American)[11], but was nonetheless 
approved by the FDA in June 2005.
When predicting drug response in individuals 
by genetic diagnosis, the current subjects of 
pharmacogenomic studies are drug-metabolizing 
enzymes, such as CYPs, the function and clinical 
significance of which are already evident. In 
addition, factors involved in pharmacokinetics, 
drug target molecules (as in the case of Iressa 
sensitivity) or factors involved in the signaling of 
target molecules are also potential subjects for 
pharmacogenomics. Such subjects include genetic 
variation in EGFR, the molecular mechanism of 
which is unknown, but has recently been found 
to contribute to drug efficacy, and many other 
molecules affecting the effects of drugs that are 
yet to be discovered.
Prediction of drug response based on molecular 
information involves many unknown factors and 
requires further research. In order to translate 
these research results into medicine, translational 
research is indispensable for demonstration 
research in human clinical research.
3 Public understanding
 for personalized medicine
3-1 Genome information
 as personal information
“Genetic information” could be regarded as 
the ultimate form of personal data but differs 
great ly f rom other personal data in many 
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ways. With the current state of science and 
technology, an individual cannot easily access 
his or her own genetic information. It can never 
be rewritten and is also transferable among 
family members, a fact demonstrated by the 
existence of familial disorders. The biggest 
problem is “the uncertainty of science” ; the 
implications of genomic information have not 
been fully understood but may have a great 
impact on the life and health of individuals. 
This indicates that, in the current situation, 
genetic analysis technology represented by 
DNA sequencing and SNP analyses goes far 
ahead of the scientific validation technology 
required to understand the significance of an 
individual’s genomic information. Basic and 
applied research for bridging the gap between 
these technologies should be conducted swiftly 
but with sensitivity, given the fact that this 
research is being performed on human subjects. 
Thus, genome information, where there is 
still a degree of scientific uncertainty, is more 
important than ordinary personal data and must 
be handled with great care. Books written from 
various standpoints on issues concerning medical 
science, medicine and personal data should help 
advance the understanding of these issues[12].
T he  requ i rement  o f  m a k i ng  a  genet ic  
diagnosis has been stipulated in guidelines 
for the administration of Iressa and other 
molecular - targeted anticancer drugs. Genes 
involved in the development of  d i seases 
represented by familial breast cancer, familial 
adenomatosis coli and hereditary non-polyposis 
colorectal cancer have been identified. When 
receiving medical treatment or notification or 
providing informed consent to the doctor before 
treatment, each person is required to possess a 
sufficient knowledge and understanding of genes. 
The significance of “understanding” is explicitly 
cited in the ethical guidel ines concerning 
human genome and genetic analysis research[13], 
which defines “informed consent” (translated as 
“setsumei ni motozuku doui” — consent based 
on explanation) as “agreement given voluntarily 
based on suf f icient pr ior explanation and 
understanding”. In that sense, an open lecture 
given upon the submission of the FDA’s final draft 
of pharmacogenomics guidelines had the very 
suggestive title of “Personalizing your Healthcare: 
The Best Consumer is an Educated Consumer” [14].
3-2 Importance of information provision
 and public understanding
The handling of genetic information has been 
stipulated at the policy level through enactment 
of the above -mentioned Act concerning the 
Protection of Personal Information and ethical 
gu idel ines f rom indiv idua l  agencies.  The 
government has proposed measures against 
bioethical issues, which are inevitably related to 
genetic information, through the establishment 
of the Bioethics Committee in the Council for 
Science and Technology Policy.
T he BT S t r ateg y  Cou nc i l  ha s  i nc luded 
“thorough public understanding —establishment 
of a system enabling appropriate judgment 
and choice by the publ ic—” as one of the 
three strategies (“research and development”, 
“industrialization” and “public understanding”) 
in the Biotechnology Strategy Outline[15]. This 
implies that the well-balanced promotion of these 
three factors is essential to the development of 
biotechnology areas including medicine and 
returning favorable outcomes to the public. Such 
development cannot be achieved without “public 
understanding” (Figure 5).
“Strategy 3: thorough public understanding —
establishment of a system enabling appropriate 
judgment and choice by the publ ic”. This 
underlines the fact that “no matter how advanced 
it is, biotechnology cannot improve people’s lives 
without achieving public understanding and 
acceptance. It is important to establish a system 
that enables the public to make appropriate 
judgments and choices concerning biotechnology 
and to improve social infrastructure to remove 
the fear and anxiety against novel technologies”. 
The strategy consists of three factors:
(1)  Enrichment of information disclosure and 
provision systems
(2)  Display of a firm government stance on 
safety and ethics
(3)  Enrichment of school education, social 
education, etc.
These factors correspond to infrastructure 
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improvement in the areas of “handl ing of 
per sona l  data”,  “bioeth ics”  and “genet ic  
education”, which are vital elements for the 
implementation of personalized medicine.
“(3) Enrichment of school education, social 
education, etc.” emphasizes that “in order to 
establish an environment where the public 
can make appropriate judgments and choices, 
it is important to increase opportunities in 
school education that allow children to acquire 
basic knowledge and acquaint themselves with 
scientific viewpoints and notions and to increase 
social education opportunities where people can 
readily learn about science. Moreover, further 
enhancement of biological education is required 
in schools, e.g. efforts to increase the number 
of students enrolled in biology classes in higher 
education and to increase the opportunities 
to take biology exams as part of the university 
entrance exam. In addition, it is important to 
support a comprehensive, cross - curriculum 
approach, such as helping students to acquire a 
science-based understanding of life in the Period 
for Integrated Study, and to realize the value 
of life during childhood.” However, Japanese 
high school students are only provided with a 
basic knowledge of genetics, and information 
concerning important terms such as “heredity” 
and “genes”, “genetic mutations” and “SNPs”, 
“mutations in somatic cells” and “mutations in 
germ cells”, which are concepts everyone would 
have to deal with in personalized medicine, is not 
provided in sufficient detail[16].
In the “Survey on public awareness of science 
and technology” conducted in February and 
March 2001[17], 74% of respondents correctly 
understood the term “DNA”. Then, another 
question was asked to veri fy how well the 
respondents understood this term; “In which part 
of your body can you find DNA?” (multiple-choice 
question). Only 33% could answer this question 
correctly. Furthermore, in a series of questions 
concerning the probability of developing genetic 
diseases, which is closely related to personalized 
medicine, only 39% (55% in the U.S.) could 
answer correctly for all four questions.
A l t h o u g h  t h e  i m p o r t a n c e  o f  p u b l i c  
understanding is advocated in the policy, “genes” 
are still not sufficiently understood by the public. 
Such lack of public understanding will become an 
obstacle to the implementation of personalized 
medicine based on appropriately informed 
consent and the promotion of public participation 
in scientific and genetic research and translational 
research that is the foundation of personalized 
medicine.
4 Suggestions
4-1 Current status in Japan
In order to achieve social acceptance of the 
genetic research that underlies personalized 
medicine, information services and educational 
ac t i v i t i e s  wh ich  a i m a t  a  be t te r  pub l ic  
understanding of genes are critical policies 
that will be required in the areas of science 
and technology and medicine. Meanwhile, 
issues concerning genes are not to be left in the 
hands of doctors or scientists; in personalized 
medicine, each of us will confront these issues 
Figure 5 : Diagram describing the three strategies
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at the point of “self-determination” of our own 
medical treatment with “self - responsibility”, 
and a lack of understanding could lead to poor 
“self-determination”. Moreover, the realization 
of personalized medicine requires participation 
of the public in translational research, i.e. 
demonstration research. Thus, it is an urgent task 
to establish a system that includes personnel and 
organizations that provide public education on 
“genetics”.
U.S.  h igh school textbooks have r icher 
and more detailed descriptions on “genetics” 
c o m p a r e d  t o  t h o s e  f o u n d  i n  J a p a n e s e  
textbooks [16]. In addition, the Genetic Alliance 
(formerly known as the Alliance of Genetic 
Support Groups, Inc.), which is an organization 
formed from more than 600 bodies supporting 
gene-related diseases and patients[18], and the 
National Council on Patient Information and 
Education, which was established based on the 
suggestion of the federal government[19], are 
involved in various activities to support patients, 
their families and the public who will eventually 
become medical service consumers. The activities 
include counseling, educational activities for 
providing high-quality information, such as the 
latest research results and scientific information, 
mediation between government, company and 
the public, management and support of patient 
groups and facilitation of public participation in 
translational research.
In Japan, we have a clinical geneticist system[20] 
and a genetic counselor certification system[21] to 
promote genetic counseling and NPOs to provide 
genetic education to the public[22], but we still 
lack an information service system that services 
the entire nation.
4-2 Establishment of an Internet-based
 information service system
The above - ment ioned sur vey on publ ic 
awareness[17] revealed that most people acquire 
science and technology information “passively” 
from mass media. In this survey, conducted four 
years ago, only 12% answered that they actually 
used the Internet to obtain information, but 
the Internet was chosen as the most attractive 
source of information that people would like to 
use in the future. In consideration of the need to 
establish a system that services the entire nation, 
the Internet is one of the most effective routes to 
provide science and technology information to 
the public.
Information that needs to be provided to the 
public is often derived from the latest scientific 
research results; it is important to immediately 
Figure 6 : Social acceptance of personalized medicine
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add and revise such research results whenever 
necessary. The system must allow easy updating 
of the information, and an Internet-based system 
would be effective in this regard. The system 
would also need to be accessible to medical 
institutions, so that the latest information and 
therapeutic methods can be made available to the 
suppliers of medical services.
In order to realize personalized medicine 
based on genome information, where advances in 
research and applications (drug development and 
clinical practice) occur in parallel, information 
must be sufficiently provided to and understood 
by the public. Considering the above-mentioned 
advantages, an Internet-based system seems to be 
the most effective and feasible way of providing 
such information.
The information can be divided into two types; 
(i) specialized information (e.g. explanation 
of molecules involved in disease development 
and prognosis and signi f icance, r isks and 
benef its) corresponding to each disease is 
required for understanding and providing 
consent when receiving personalized medicine 
or participating in translational research, and 
(ii) basic information to serve as the basis for 
understanding such specialized information. The 
former requires a system to enable one-on-one 
counseling or answering questions whenever 
required, while the latter can be integrated 
into school education or effectively provided 
through open lectures. Human resources capable 
of counseling or responding to the public will 
be necessary, and systems to develop human 
resources such as genetic counselors will also 
need to be establ ished. The establ ishment 
of an information service system would also 
be an effective tool to facilitate, support and 
supplement such counseling.
Since such an information service system 
involves interactions between areas such as 
science and technology, medicine, and school 
education, it would require a cross -ministry 
linkage led by the Ministry of Education, Culture, 
Sports, Science and Technology and the Ministry 
of Health, Labour and Welfare. Moreover, since 
the area of medicine closely involves drugs and 
diagnostic equipment, the system must include 
information from private companies working 
in such areas. Thus, it is necessary to establish 
an information service organization based on 
linkages between industry, government and 
academia.
P e r s o n a l i z e d  m e d i c i n e  i s  g e n e r a l l y  
considered as an ideal form of medicine, but 
its implementation requires DNA for molecular 
diagnoses when using molecular - targeted 
anticancer drugs and participation of the public 
in translational research, i.e. demonstration 
research. Most of all, we must fully understand 
doctors’ explanations when deciding on the 
therapeutic strategy for ourselves or our families. 
Thus, the rapid provision of h igh - qual it y 
information to the public is the most important 
task to secure public safety.
Glossary
*1 Pharmacogenomics
 The concept of analyzing the difference in 
drug response among individuals by utilizing 
human genome information and genome 
analysis techniques.
*2 Molecular-targeted anticancer drugs
 Anticancer drugs that are developed based 
on the molecular mechanism of cancer 
development and target the molecules 
responsible for cancer development.
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